The estimated Net Worth of Arthur L Rosenthal is at least $1.37 Millón dollars as of 15 June 2022. Arthur Rosenthal owns over 1,346 units of LivaNova PLC stock worth over $1,125,941 and over the last 8 years he sold LIVN stock worth over $0. In addition, he makes $239,890 as Independent Director at LivaNova PLC.
Sign up
Arthur Rosenthal LIVN stock SEC Form 4 insiders trading
Arthur has made over 8 trades of the LivaNova PLC stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 1,346 units of LIVN stock worth $63,868 on 15 June 2022.
The largest trade he's ever made was exercising 3,327 units of LivaNova PLC stock on 5 August 2017 worth over $157,866. On average, Arthur trades about 913 units every 146 days since 2016. As of 15 June 2022 he still owns at least 23,729 units of LivaNova PLC stock.
You can see the complete history of Arthur Rosenthal stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Arthur Rosenthal biography
Dr. Arthur J. Rosenthal Ph.D. serves as Independent Director of the Company. Arthur Rosenthal, PhD retired from EyeCue, Inc., a development-stage medical device company working on a guided biopsy for lower and upper gastrointestinal cancer screening, after serving as co-founder and CEO from 2011 to 2015. Dr. Rosenthal also served as Professor of Practice in the Biomedical Engineering Department at Boston University from 2010 to 2015. Prior to co-founding EyeCue in 2011, Dr. Rosenthal served as President and CEO of Cappella, Inc., a development-stage company focused on novel device solutions for coronary artery disease (2009 to 2011); CEO of Labcoat, Ltd., a development-stage drug-eluting stent technology company, from 2005 until its acquisition by Boston Scientific Corporation in 2008; Senior Vice President, Chief Science Officer and Executive Committee Member of Boston Scientific, a medical device manufacturer (2000 to 2005); and Senior Vice President, Corporate Officer and Chief Development Officer at Boston Scientific (1994 to 2000). Dr. Rosenthal earned his Bachelor Degree in Bacteriology from the University of Connecticut and a Ph.D in Biochemistry from the University of Massachusetts.
What is the salary of Arthur Rosenthal?
As the Independent Director of LivaNova PLC, the total compensation of Arthur Rosenthal at LivaNova PLC is $239,890. There are 11 executives at LivaNova PLC getting paid more, with Damien McDonald having the highest compensation of $7,131,930.
How old is Arthur Rosenthal?
Arthur Rosenthal is 73, he's been the Independent Director of LivaNova PLC since 2015. There are no older and 20 younger executives at LivaNova PLC.
What's Arthur Rosenthal's mailing address?
Arthur's mailing address filed with the SEC is 20 EASTBOURNE TERRACE, , LONDON, X0, W2 6LG.
Insiders trading at LivaNova PLC
Over the last 9 years, insiders at LivaNova PLC have traded over $79,802,010 worth of LivaNova PLC stock and bought 4,000 units worth $268,530 . The most active insiders traders include William A Kozy, Two S.C.A.Tower 6 S. A R.L.... y Peter M Wilver. On average, LivaNova PLC executives and independent directors trade stock every 10 days with the average trade being worth of $315,922. The most recent stock trade was executed by Peter M Wilver on 15 June 2024, trading 2,680 units of LIVN stock currently worth $127,166.
What does LivaNova PLC do?
livanova plc is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. our advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems.at livanova, we understand the importance of bringing both clinical and economic value to our customers. we are a strong, market-leading medical technology and services company, offering a diverse product portfolio and global reach. livanova is listed on the nasdaq stock exchange under the ticker symbol “livn.” livanova has approximately 3,000 employees worldwide. we are headquartered in london (uk) and maintain a presence in more than 100 countries. livanova is a worldwide leader in advanced circulatory support, cardiopulmonary and neuromodulation, dedicated to creating meaningful products and therapies that transform lives each and every day.
What does LivaNova PLC's logo look like?
Complete history of Arthur Rosenthal stock trades at LivaNova PLC
LivaNova PLC executives and stock owners
LivaNova PLC executives and other stock owners filed with the SEC include:
-
Damien McDonald,
Chief Executive Officer, Director -
Keyna Skeffington,
Senior Vice President, General Counsel and Company Secretary -
Alistair Simpson,
Special Advisor -
Edward Andrle,
Special Advisor -
Damien McDonald,
CEO & Director -
Keyna Pidcock Skeffington,
Sr. VP, Gen. Counsel & Corp. Sec. -
Alex Shvartsburg,
CFO and Corp. VP of Financial Planning, Analysis & International Region -
Daniel Moore,
Independent Chairman of the Board -
Hugh Morrison,
Independent Director -
Alfred Novak,
Independent Director -
Francesco Bianchi,
Independent Director -
Arthur Rosenthal,
Independent Director -
Andrea Saia,
Independent Director -
Sharon O'Kane,
Independent Director -
William Kozy,
Independent Director -
Stacy Seng,
Independent Director -
Marco Dolci,
Head of Global Operations and R&D -
Roy Khoury,
President - International, Senior Vice President - Global Strategic Marketing -
Trui Hebbelinck,
Chief Human Resource Officer -
Alex Shvartsburg,
Interim Chief Financial Officer -
Stephanie Bolton,
Pres of International Region -
Paul R. Buckman,
Pres of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement -
Dr. Bryan D. Olin Ph.D.,
Sr. VP & Head of Product Devel. - Neuromodulation -
Trui Hebbelinck,
Chief HR Officer -
Matthew Joseph Dodds III,
Sr. VP of Corp. Devel. -
Deanna Wilke,
Director of Corp. Communications -
Lullo Stefano Di,
Pres Cardiac Rhythm Mgmt -
Michel Darnaud,
President Cardiac Surgery -
Thad Allen Huston,
Chief Financial Officer -
Vivid Sehgal,
CFO -
Two S.C.A.Tower 6 S. A R.L....,
-
Jacques Gutedel,
President Intercontinental -
Stefano Gianotti,
Director -
Piero Vecchi,
VP & Controller -
Pritpal Shinmar,
SR VP Global Market Access -
Robert Jason Richey,
President, Neuromodulation -
Douglas John Manko,
Chief Accounting Officer -
David S Wise,
SR VP HR & IT -
Todd C Schermerhorn,
Director -
Ahmet Tezel,
Chief Innovation Officer -
Brian Sheridan,
SR VP Genl Counsel & Secretary -
Andre Michel Ballester,
CEO -
Demetrio Mauro,
Chief Integration Officer -
James Christopher Barry,
Director -
Peter M Wilver,
Director -
Brooke Story,
Director -
Michael Damon Hutchinson,
Chief Legal Officer -
Stephanie Bolton,
President, Global Epilepsy -
Vladimir Makatsaria,
Chief Executive Officer